Summit Therapeutics (SMMT)
NASDAQ:SMMT
SMMT Stock Chart & Stats
$18.69
$0.42(2.31%)
At close: 4:00 PM EST
$18.69
$0.42(2.31%)
Day’s Range― - ―
52-Week Range$13.83 - $36.91
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.49M
Market Cap
$14.49B
Enterprise Value$13.71B
Total Cash (Recent Filing)$713.45M
Total Debt (Recent Filing)$20.89M
Price to Earnings (P/E)―
Beta2.67
Next Earnings
May 07, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding775,372,700
10 Day Avg. Volume3,187,445
30 Day Avg. Volume2,487,378
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)19.85
Price to Sales (P/S)0.00
P/FCF Ratio-40.41
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-126.52K
Enterprise Value/Ebitda-17.11
Forecast
1Y Price Target
$31.78Price Target Upside70.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.16
Revenue Forecast (FY)$5.47M
Bulls Say, Bears Say
Bulls Say
Clinical CatalystA positive interim progression-free survival result in the HARMONi-3 squamous cohort would likely drive a sharp share-price reaction and enable more rapid engagement with the FDA toward approval.
Pricing And Market AccessDelayed entry of Keytruda biosimilars enhances ivonescimab's ability to secure favorable payer contracts and sustain stronger net pricing during initial commercialization.
Regulatory ReadinessFDA acceptance of a biologics license application together with visible commercial capability build-out signals reduced near-term regulatory risk and preparedness to scale if approval is achieved.
Bears Say
Endpoint UncertaintyUncertainty that an interim progression-free survival benefit will translate into an overall survival advantage increases approval risk and keeps valuation contingent on confirmatory survival data.
Global Trial ComplexityA global trial design with substantial participation from China complicates extrapolation to U.S. and European populations and raises the likelihood of additional regulatory scrutiny or requests for further data.
Valuation And Financing RiskHeavy reliance on definitive overall survival evidence heightens downside valuation risk and raises the prospect of future financing or shareholder dilution if survival results disappoint.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $13.83 and its highest was $36.91 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $14.49B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 30 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Feb 23, 2026. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.077 by -$0.213.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 775,372,700 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.077. Following the earnings report the stock price went up 0.186%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.78 (70.04% Upside)
$31.78 (70.04% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.27%
12-Months-Change
Fundamentals
Return on Equity
-296.82%
Trailing 12-Months
Asset Growth
72.46%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong set of clinical and operational achievements: multiple positive Phase III readouts, broad global development, robust patient exposure, strategic collaborations, a healthy cash balance ($713.4M), manufacturing transfer to the U.S., and an accepted BLA with a November 14, 2026 PDUFA date. Key risks remain around demonstrating statistically significant overall survival for U.S. approval in the EGFR setting, OS immaturity at the interim PFS readout for HARMONi-3 squamous, increased near-term R&D spending (non-GAAP op expenses +~9.6% Q/Q), and reliance on partner-generated data from China which may require bridging for global regulatory bodies. On balance, the highlights (clinical momentum, approvals in China, partnerships, cash runway, manufacturing readiness) outweigh the challenges, but the path to full U.S. approval and broader commercialization depends on forthcoming OS data and regulatory interactions.View all SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$31.78
▲(70.04% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---